UK considers gauging latent vCJD infection with tests on all postmortems
This article was originally published in Clinica
Executive Summary
The UK government is considering extending postmortem examinations with tests for variant Creutzfeldt-Jakob disease (vCJD), in order to better gauge the extent of latent infection across the entire population. Concerned that 166 UK deaths to date may not reflect the true prevalence, with the significant risk that this poses to transmission through surgery and blood transfusion, the Department of Health (DoH) wants postmortems to include tests on tissues that are known to accumulate the prion protein responsible for vCJD, such as the spleen and the brain. Some 115,000 postmortems are ordered by coroners every year in England alone. The Coroners' Society for England and Wales has criticised the initiative as "inappropriate", but the Health Protection Agency and DoH are reportedly keen to develop the plans and are assessing the practical and legal implications.
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.